These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10024671)

  • 1. Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients.
    Hung G; Faudoa R; Li X; Xeu Z; Brackmann DE; Hitselberg W; Saleh E; Lee F; Gutmann DH; Slattery W; Rhim JS; Lim D
    Int J Oncol; 1999 Mar; 14(3):409-15. PubMed ID: 10024671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.
    Hung G; Li X; Faudoa R; Xeu Z; Kluwe L; Rhim JS; Slattery W; Lim D
    Int J Oncol; 2002 Mar; 20(3):475-82. PubMed ID: 11836557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
    Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
    Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
    Petrilli AM; Fernández-Valle C
    Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
    Tamura R; Morimoto Y; Sato M; Kuranari Y; Oishi Y; Kosugi K; Yoshida K; Toda M
    J Neurooncol; 2020 Jan; 146(2):265-273. PubMed ID: 31897926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas.
    Sainz J; Huynh DP; Figueroa K; Ragge NK; Baser ME; Pulst SM
    Hum Mol Genet; 1994 Jun; 3(6):885-91. PubMed ID: 7951231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment.
    Morris KA; Parry A; Pretorius PM
    Br J Radiol; 2016 Sep; 89(1065):20160110. PubMed ID: 27452262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laryngeal plexiform schwannoma as first symptom in a patient with neurofibromatosis type 2.
    Nagato T; Katada A; Yoshizaki T; Kunibe I; Takahara M; Katayama A; Hayashi T; Harabuchi Y
    Clin Neurol Neurosurg; 2010 Jul; 112(6):505-8. PubMed ID: 20303213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene discovery using a human vestibular schwannoma cDNA library constructed from a patient with neurofibromatosis type 2 (NF2).
    Halum SL; Erbe CB; Friedland DR; Wackym PA
    Otolaryngol Head Neck Surg; 2003 Mar; 128(3):364-71. PubMed ID: 12646839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
    Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
    J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
    Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
    Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients.
    Rosenbaum C; Kluwe L; Mautner VF; Friedrich RE; Müller HW; Hanemann CO
    Neurobiol Dis; 1998 Jul; 5(1):55-64. PubMed ID: 9702788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas.
    Hamada Y; Iwaki T; Fukui M; Tateishi J
    Surg Neurol; 1997 Oct; 48(4):395-400. PubMed ID: 9315139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of multiple tumors in neurofibromatosis type 2 patients.
    Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
    Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurofibromatosis type 2 gene is inactivated in schwannomas.
    Twist EC; Ruttledge MH; Rousseau M; Sanson M; Papi L; Merel P; Delattre O; Thomas G; Rouleau GA
    Hum Mol Genet; 1994 Jan; 3(1):147-51. PubMed ID: 8162016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced RAC1 activity inhibits cell proliferation and induces apoptosis in neurofibromatosis type 2(NF2)-associated schwannoma.
    Wang Y; Wang B; Li P; Zhang Q; Liu P
    Neurol Res; 2017 Dec; 39(12):1086-1093. PubMed ID: 28934903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
    Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
    Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas.
    Kukutla P; Ahmed SG; DuBreuil DM; Abdelnabi A; Cetinbas M; Fulci G; Aldikacti B; Stemmer-Rachamimov A; Plotkin SR; Wainger B; Sadreyev RI; Brenner GJ
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1508-1514. PubMed ID: 34053190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
    Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
    Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.